Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • According to sales estimates from analysts polled by Thomson-Reuters, the company is among the best with regard to growth.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 11.73 EUR
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at EUR 21.13.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
  • With an expected P/E ratio at 104.25 and 72.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
EVOTEC AG192.93%3 261
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC33.89%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, IN..208.84%10 522
SEATTLE GENETICS, INC.21.30%9 134
IONIS PHARMACEUTICALS INC33.58%8 007
QIAGEN NV17.88%7 878
ALKERMES PLC-8.08%7 772
ICON PLC52.07%6 141
EXACT SCIENCES CORPORATION248.95%5 854
INC RESEARCH HOLDINGS INC5.61%5 782
CHARLES RIVER LABORATORIES ..50.54%5 481
UNITED THERAPEUTICS CORPORA..-16.25%5 257
PRA HEALTH SCIENCES INC49.49%5 193
More Results
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
P/E ratio 2017 104,25
P/E ratio 2018 72,17
EV / Sales 2017 12,0x
EV / Sales 2018 8,87x
Capitalization 2 768 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart EVOTEC AG
Duration : Period : Day
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Duration : Period : Week
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders